Human Microbiome Sequencing Market: By Microbes; Anatomy; Technology; Disorder; Diagnosis; Application; & Geography - Forecast 2018 to 2023

  • ID: 4532404
  • Report
  • 145 pages
  • IndustryARC
1 of 3
Human microbiome is a collective genome of microorganisms that reside inside and outside of the body ranging from pathogenic to beneficial. Microbiota hosts on a biotic as well as an abiotic body.

The Human Microbiome Sequencing market is broadly classified on the basis of various parameters. The market has been divided based on types of microbes- Bacteria, Archae, Fungi and Virus. On the basis of human anatomy- Skin, Conjunctiva, Gut, Other body parts. The segmentation is also by the sequencing technology- Traditional and Next Generation. On the basis of Disorders, the market has been segmented as Gastrointestinal, Metabolic, Oncology and other serious disorders and on the basis of diagnosis- analyzers, reagents and other solutions. The market has been split by the application areas such as Healthcare & Pharmaceuticals, Food & Beverage and others also by End-Users in Testing Centres, Research Labs and other areas, as well as based on geographical analysis.

The market is led by U.S. region as the the growing number of startups and huge investments by ventures in pharmaceutical and medical fields, as well as food & beverage industry drive the growth. The growing healthcare tourism in Middle East and APAC regions will significantly drive the market for Human Microbiome Sequencing in these markets. APAC region will have the fastest growing market during the forecast period as improving medical infrastructure and growing programs driving medical procedures in this region drive the market.
Key market players- uBiome, Evolve BioSystems, Epibiome and many others. The advancement in medical and food technologies and continuous investments by big industry tycoons and government, and penetration of start-ups in this market, indicates better prospective in Microbiome Sequencing Market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Human Microbiome Sequencing Market Overview

2. Executive Summary

3. Human Microbiome Sequencing – Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End user profiling
3.5. Top 5 Financials Analysis

4. Human Microbiome Sequencing – Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition

5. Human Microbiome Sequencing – Market Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis

6. Human Microbiome Sequencing – By Microbes
6.1. Bacteria
6.2. Archaea
6.3. Fungi
6.4. Virus
6.5. Others

7. Human Microbiome Sequencing – By Anatomy
7.1. Skin
7.2. Conjunctiva
7.3. Gut
7.4. Vaginal
7.5. Placenta
7.6. Uterus
7.7. Oral Cavity
7.8. Lung
7.9. Biliary Tract
7.10. Others

8. Human Microbiome Sequencing – By Technology
8.1. Traditional
8.2. Next Generation
8.2.1. Shotgun Metagenomic Sequencing
8.2.2. 16S ribosomal RNA Sequencing
8.2.3. Microbial Transcriptomics
8.2.4. Microbial Whole-Genome Sequencing
8.2.5. Computational Tools
8.2.6. Others

9. Human Microbiome Sequencing – By Disorder
9.1. Gastrointestinal Disorder
9.2. Infectious Diseases
9.3. Metabolic Disorder
9.4. Immunology
9.5. Oncology
9.6. Central Nervous System
9.7. Others

10. Human Microbiome Sequencing – By Diagnosis
10.1. Analyzers
10.2. Reagents
10.3. Others

11. Human Microbiome Sequencing – By Application
11.1. Healthcare
11.2. Pharmaceutical
11.3. Food & Beverages
11.4. Others

12. Human Microbiome Sequencing – By End-Use
12.1. Testing Centres
12.2. Research Labs
12.3. Others

13. Human Microbiome Sequencing - By Geography
13.1. Introduction
13.2. Americas
13.2.1. US
13.2.2. Canada
13.2.3. Mexico
13.2.4. Brazil
13.2.5. Argentina
13.2.6. Others
13.3. Europe
13.3.1. Germany
13.3.2. U.K.
13.3.3. France
13.3.4. Spain
13.3.5. Italy
13.3.6. Others
13.4. APAC
13.4.1. Japan
13.4.2. China
13.4.3. India
13.4.4. South Korea
13.4.5. Australia
13.4.6. Others
13.5. ROW
13.5.1. Middle East
13.5.2. Africa

14. Market Entropy
14.1. New Product Launches
14.2. M&As, Collaborations, JVs and Partnerships

15. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
15.1. uBiome
15.2. Evolve BioSystems
15.3. Epibiome
15.4. AO Biome, LLC
15.5. Yakult
15.6. ISOThrive
15.7. Rebiotix
15.8. Inocucor
15.9. Cambrooke Therapeutics
15.10. CosmosID

16. Appendix
16.1. Abbreviations
16.2. Sources
16.3. Research Methodology
16.4. Bibliography
16.5. Compilation of Expert Insights
16.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll